Business Context and Reporting Period
Tarsus Pharmaceuticals, Inc. (TARS), a Delaware corporation, filed this Form 8-K on February 29, 2024. The filing reports the entry into a material definitive agreement for a public offering of common stock and pre-funded warrants.
Key Financial Metrics and Transaction Details
- Offering Size: 2,812,500 shares of common stock and pre-funded warrants for 312,500 shares.
- Public Price: $32.00 per share and $31.9999 per pre-funded warrant.
- Underwriter Price: $30.08 per share and $30.0799 per pre-funded warrant.
- Expected Net Proceeds: Approximately $93.7 million (excluding underwriting discounts, commissions, and expenses).
- Over-Allotment Option: Underwriters have a 30-day option to purchase up to an additional 468,750 shares.
- Expected Closing Date: March 5, 2024.
Material Changes
This filing represents a significant capital raise event. The company entered into an Underwriting Agreement with Goldman Sachs & Co. LLC, BofA Securities, Inc., and Guggenheim Securities, LLC. The filing does not provide comparative financial data (revenue, profit, or cash flow) as it is a current report regarding a specific transaction rather than a periodic financial statement.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the anticipated closing of the offering and the amount of net proceeds. Key risks include the company's ability to satisfy customary closing conditions on a timely basis or at all. The transaction is subject to the satisfaction of these conditions.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received on or after March 5, 2024.
- Confirm whether the underwriters exercised the 30-day option to purchase additional shares.
- Review the final prospectus supplement for updated use of proceeds and risk factors.
- Monitor the company's cash position post-closing to assess runway for clinical development.